1,100+ treatments performed – Prof. Elke Jaeger is a top German oncologist specializing in Burkitt's lymphoma at Nordwest Clinic.
Dr. Michael Shapira specializes in Bone Marrow Transplantation at Sourasky Medical Center (Ichilov), with extensive experience treating blood cancers.
Dr. Fredi Aviv has over 34 years of experience of experience treating blood cancers at Tel Aviv's leading Sourasky Medical Center.
Pioneering hematologist specializing in Burkitt's lymphoma at Intrarat Hospital – trained at Thammasat University, a leading center for hematology in Thailand.
Dr. Dror Levin specializes in pediatric hematology oncology, focusing on Burkitt's lymphoma at Sourasky Medical Center in Tel Aviv.
Dr. Ayhan Gulsan specializes in Burkitt's lymphoma with advanced training in stem cell transplantation at Duke University and Fred Hutchinson Cancer Research Center.
A leading hematology expert recognized by the American Society of Hematology, Dr. Yair treats patients at Tel Aviv's Sourasky Medical Center.
Prof. Wolfgang Köstler is a distinguished Austrian oncologist specializing in targeted cancer therapies, with over two decades of experience.
Dr. Fox specializes in Burkitt's lymphoma treatment, blending innovative therapies with extensive research on haemato-oncological diseases at Medical Center in Solingen.
Professor Drach specializes in oncology with a focus on Burkitt's lymphoma, offering expert consultations at Confraternitaet Private Hospital.
Dr. Eckhart Weidmann leads the Hematology sector at Nordwest Clinic with over 36 years of experience of practice in treating blood disorders.
Specialized in Medical Oncology at Akdeniz University – Dr. Alemdar focuses on Burkitt's lymphoma and other hematological cancers.
Dr. Hila Magen, MD, leads the Multiple Myeloma and Amyloidosis Unit at Sheba Medical Center. She is a hemato-oncologist with over 35 years of experience. She is a leading Israeli expert in multiple myeloma and plasma cell disorders.
She runs a program that provides personalized care and early access to clinical trials. This includes CAR-T therapy for high-risk and relapsed or refractory myeloma and amyloidosis. Dr. Magen is a principal investigator in point-of-care CAR-T studies. She brings new immunotherapies into routine care.
Training: Fellowships in Multiple Myeloma (UAMS) and Lymphocytic Leukemia (MD Anderson). Academic: Instructor, Tel Aviv University. Research: Author of 100+ publications, contributor to landmark myeloma studies, and reviewer for international journals.
Dr. Hana Golan, MD, heads the Pediatric Hemato-Oncology and Bone Marrow Transplantation (BMT) Division at Sheba Medical Center. She specializes in childhood cancers, with a focus on neuroblastoma and other high-risk solid tumors.
She leads one of the region’s most advanced pediatric oncology programs. She manages complex, high-risk cases and practices at a hospital ranked in the global top 10.
She is the principal investigator of the High-Risk Neuroblastoma ESIOP protocol. She serves as an investigator in international Phase I/II trials and as the national coordinator of multicenter oncology protocols. She led the development of computerized chemotherapy protocols and patient databases to improve safety.
She earned her MD from the Technion. She completed residencies in pediatrics and pediatric hemato-oncology at Sheba. She conducted advanced research in transplantation immunology at the Weizmann Institute. She is board-certified in Pediatrics and Pediatric Hematology-Oncology. She is a Senior Lecturer at the Sackler Faculty of Medicine, Tel Aviv University. Her research focuses on cancer stem cells, targeted therapies, treatment-resistant malignancies, and cannabinoid-related oncology.
Prof. Avichai Shimoni, MD, is Director of Bone Marrow Transplantation at Sheba Medical Center. He is a hemato-oncologist with over 30 years of experience in bone marrow transplantation, cellular therapies, and advanced blood cancer care.
He leads a high-volume program for complex, high-risk blood cancers. He performs allogeneic and autologous transplants. He also provides CAR T-cell therapy for leukemia, lymphoma, and multiple myeloma. He completed a bone marrow transplantation fellowship at MD Anderson Cancer Center.
He is Chairman of Hematology at Tel Aviv University and a Professor of Hematology. He has authored more than 250 scientific papers. His research focuses on CAR T-cell therapy and stem cell transplantation. He is often listed among Israel's Best Doctors (Forbes 2025 and 2026).
Dr. Abraham Avigdor, MD, is Director of the Institute of Hematology and Co‑Director of the Hematology & Bone Marrow Transplantation Division at Sheba Medical Center. He is an international leader in lymphoma, CAR‑T, and advanced hemato‑oncology with more than 35 years of experience. His clinical focus includes lymphomas, multiple myeloma, and complex blood cancers.
He is a pioneer in CAR‑T integration. He leads cellular therapy and bone marrow transplantation programs (autologous and allogeneic). He also advances stem cell therapies and precision diagnostics, including PET/CT‑based prognostics. His work includes immunotherapy and targeted regimens and the development of innovative, data‑driven protocols.
He collaborates with LYSA, EMCL, and international PET groups. He has authored more than 130 publications. Key roles include Founder and President of the Israeli Lymphoma Working Group, former Chair of the Israeli Lymphoma Study Group, and Senior Lecturer at Tel Aviv University. Education: MD, Ben‑Gurion University; residency, Sheba Medical Center; postdoctoral fellowship, Weizmann Institute. Awards include the Knesset Prize, the Israeli Ministry of Health Award, and the Sackler Prize.